From: Barron’s
By: Josh Nathan-Kazis

 

 

 

 

 

 

 

Biogen stock was slipping on Friday morning as one analyst warned that the company’s drug for multiple sclerosis could be losing ground to new competitors.

Citing data from a proprietary survey of doctors treating MS patients, PiperJaffray analyst Christopher Raymond outlined threats to the market share of Biogen’s Tysabri from Novartis’ (NVS) newly-approved MS drug Mayzent and Roche’s (CH:ROG) drug Ocrevus…(read more).